• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Bryn Pharma raises $17.5 million to fund regulatory and commercial activities for its epinephrine nasal spray

Bryn Pharma, which recently announced that it would use Aptar's Bidose nasal device for delivery of its BRYN-NDS1C intranasal epinephrine, said that it has raised $17.5 million that it will use to prepare for US regulatory approval and commercialization of the nasal spray. BRYN-NDS1C has received Fast Track designation from the FDA, and the company plans to pursue … [Read more...] about Bryn Pharma raises $17.5 million to fund regulatory and commercial activities for its epinephrine nasal spray

TFF Pharmaceuticals announces IPO

TFF Pharmaceuticals, which is developing DPI formulations based on its thin film freezing (TFF) technology, has announced an initial public offering of 4,400,000 shares of common stock at $5.00 per share. Earlier this year TFF announced that it had raised $8.17 million through a Series A preferred stock offering. The company said that it expects to use the net … [Read more...] about TFF Pharmaceuticals announces IPO

Studies show Penthrox is superior to standard of care for acute trauma pain

Medical Developments International (MDI) has announced data from multiple European studies demonstrating the benefits of MDI's Penthrox methoxyflurane inhaler for the treatment of pain from acute trauma. Among the findings announced, Penthrox was shown to be superior to intravenous morphine, NSAIDS, paracetamol (acetaminophen), and ketoprofen in trauma settings; … [Read more...] about Studies show Penthrox is superior to standard of care for acute trauma pain

FDA clears BlueWillow IND for intranasal anthrax vaccine

The FDA has cleared BlueWillow Biologics' IND for its BW-1010 intranasal anthrax vaccine, and a Phase 1 trial of the vaccine is planned for later this year, the company said. Earlier this year, BlueWillow (formerly NanoBio) announced that it had received a patent for the anthrax vaccine, which is formulated with the company's NanoVax adjuvant. BW-1010 is in … [Read more...] about FDA clears BlueWillow IND for intranasal anthrax vaccine

Seelos Therapeutics says it has amended agreement for development of its intranasal ketamine

Seelos Therapeutics has announced an amendment of its agreement with Vyera Pharmaceuticals regarding development of SLS-002 intranasal ketamine. According to Seelos, the company will now not be required to conduct a Phase 3 trial and will make cash and stock payments to Vyera instead of a milestone that would be due on initiation of a Phase 3 trial. Seelos said … [Read more...] about Seelos Therapeutics says it has amended agreement for development of its intranasal ketamine

Bryn Pharma to use Aptar’s Bidose nasal device for epinephrine delivery

Bryn Pharma (formerly Epi-Now) announced that it has signed a deal with Aptar Pharma for worldwide exclusive rights to use Aptar's Bidose nasal delivery device for its BRYN-NDS1C intranasal epinephrine for the treatment of anaphylaxis. The company said that it has recently completed dosing in a pivotal clinical trial using the device. According to Bryn's website, … [Read more...] about Bryn Pharma to use Aptar’s Bidose nasal device for epinephrine delivery

Circassia announces US launch of Duaklir Pressair for the treatment of COPD

Circassia Pharmaceuticals has announced the US launch of Duaklir aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. The FDA approved Duaklir Pressair in April 2019. Circassia acquired the US rights to Duaklir and Tudorza Pressair from AstraZeneca in 2017. Circassia Chief Executive Steve Harris commented, “The US launch of Duaklir represents a … [Read more...] about Circassia announces US launch of Duaklir Pressair for the treatment of COPD

AZTherapies raises $26.3 million in Series C financing

AZTherapies said that the company had closed a $26.3 million Series C preferred equity financing round that will fund completion of a Phase 3 trial of its ALZT-OP1 inhaled cromolyn/oral ibuprofen for the treatment of Alzheimer's disease. The COGNITE study was initiated in 2015 and is expected to be completed by the end of 2020. The company said that proceeds from … [Read more...] about AZTherapies raises $26.3 million in Series C financing

United Therapeutics returns rights to Respira’s RT234 vardenafil DPI

Respira Therapeutics has announced that United Therapeutics will end its collaboration with the company and will return all rights to Respira's RT234 vardenafil DPI, which is in Phase 2 development for the relief of symptoms of pulmonary arterial hypertension (PAH). The companies had announced the licensing deal and an investment by United Therapeutics in Respira in … [Read more...] about United Therapeutics returns rights to Respira’s RT234 vardenafil DPI

English High Court dismisses GSK claims in AirFluSal Forspiro case

According to Vectura, the English High Court has dismissed all claims in a "passing off" case brought by GlaxoSmithKline in which GSK charged that of Sandoz's AirFluSal Forspiro DPI looks too similar to Seretide Accuhaler. Both inhalers and their packaging feature a similar shade of purple. Vectura noted that GSK has filed similar cases in a number of European … [Read more...] about English High Court dismisses GSK claims in AirFluSal Forspiro case

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 53
  • Page 54
  • Page 55
  • Page 56
  • Page 57
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews